UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000033439
Receipt number R000038128
Scientific Title Metabolic effects of bariatric surgery (laparoscopic sleeve gastrectomy) on endocrine abnormalities
Date of disclosure of the study information 2018/08/01
Last modified on 2021/07/20 12:44:36

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Metabolic effects of bariatric surgery (laparoscopic sleeve gastrectomy) on endocrine abnormalities

Acronym

Metabolic effects of bariatric surgery on endocrine abnormalities

Scientific Title

Metabolic effects of bariatric surgery (laparoscopic sleeve gastrectomy) on endocrine abnormalities

Scientific Title:Acronym

Metabolic effects of bariatric surgery on endocrine abnormalities

Region

Japan


Condition

Condition

Obese patients with metabolic abonormalities

Classification by specialty

Endocrinology and Metabolism Adult

Classification by malignancy

Others

Genomic information

YES


Objectives

Narrative objectives1

To examine the metabolic effects of bariatric surgery on endocrine abnormalities

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

The improvement in histlogic features of NAFLD,as assessed with a composite of standardized scores for steatosis,lobular inflammation,hepatocellular ballooning,and fibrosis.Disease activity is assessed with the nonalcoholic fatty liver disease activity score,which is based on a standardized grading system for steatosis(on a scale of 0 to 3),lobular inflammation(on a scale of 0 to 3),and hepatocellular ballooning(on a scale of 0 to 2),with higher scores indicating increasing severity.

Key secondary outcomes

Change from baseline in liver enzymes
Change from baseline in body composition
Change from baseline in fasting plasma glucose level and glucose metabolism assessed with arginine tolerance test
Changes from baseline in organ-specific insulin sensitivity and glucagon response during a euglycemic hyperinsulinemic clamp study
Change from baseline in lipid profile
Change from baseline in renal function and electrolyte balances
Change from baseline in hepatokine (Selenoprotein P, LECT2) levels
Change from baseline in organ-specific fat accumulation
Change from baseline in oxidative and non-oxidative glucose disposal
Change from baseline in respiratory quotients
Change from baseline in energy expenditure
Change from baseline in autonomic nerve function. This is performed by power-spectrum analyses of heart rate variability
Changes from baseline in minerals and bone metabolism
Changes from baseline in endothelial functions
Factors associated with the changes in autonomic nerve function, organ-specific fat accumulation, and glucagon response.
Changes from baseline in gene expression profiles in the liver and blood cells
Changes from baseline in microRNAs and exosome contents
Epigenomic changes from baseline in genes of the liver and blood cells
Changes in severity index of sleep apnea by sleeping polysomnography
Improvement of QOL evaluation by SF-36 questionnaire
Motor effect analysis by I-PAQ
Nutritional assessment by meal behavior questionnaire and FFQg


Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Uncontrolled

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

1

Purpose of intervention

Treatment

Type of intervention

Other

Interventions/Control_1

bariatric surgery

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

1)BMI 35 kg/m2 or more
2)Patients with metabolic disorders
3)at least absolved 6 months of failed conservative treatment for morbid obesity
4)Age over 20 years old
5)participants provided written informed consent

Key exclusion criteria

1)Patients who participated in other clinical studies (trials) within 3 months before the study
2)Inability to participate in the study as assessed by the investigators

Target sample size

40


Research contact person

Name of lead principal investigator

1st name Toshinari
Middle name
Last name Takamura

Organization

Kanazawa University Graduate School of Medical Sciences

Division name

Department of Endocrinology and Metabolism

Zip code

920-8641

Address

13-1 Takara-machi, Kanazawa, Ishikawa

TEL

076-265-2234

Email

ttakamura@m-kanazawa.jp


Public contact

Name of contact person

1st name Yumie
Middle name
Last name Takeshita

Organization

Kanazawa University Graduate School of Medical Sciences

Division name

Department of Endocrinology and Metabolism

Zip code

920-8641

Address

13-1 Takara-machi, Kanazawa, Ishikawa

TEL

076-265-2234

Homepage URL


Email

takeshita@m-kanazawa.jp


Sponsor or person

Institute

Kanazawa University Graduate School of Medical Sciences
Department of Endocrinology and Metabolism

Institute

Department

Personal name



Funding Source

Organization

None

Organization

Division

Category of Funding Organization

Other

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Innovative Clinical Research Center, Kanazawa University.

Address

13-1 takaramachi kanazawa

Tel

076-265-2110

Email

rinri@adm.kanazawa-u.ac.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

金沢大学附属病院(石川県金沢市)


Other administrative information

Date of disclosure of the study information

2018 Year 08 Month 01 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Open public recruiting

Date of protocol fixation

2018 Year 04 Month 06 Day

Date of IRB

2018 Year 04 Month 06 Day

Anticipated trial start date

2018 Year 04 Month 06 Day

Last follow-up date

2025 Year 03 Month 31 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2018 Year 07 Month 18 Day

Last modified on

2021 Year 07 Month 20 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000038128


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name